Motley Fool Wealth Management LLC Buys 126,970 Shares of BioMarin Pharmaceutical Inc. $BMRN

Motley Fool Wealth Management LLC grew its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 36.4% during the second quarter, Holdings Channel.com reports. The firm owned 475,949 shares of the biotechnology company’s stock after acquiring an additional 126,970 shares during the period. BioMarin Pharmaceutical accounts for about 1.6% of Motley Fool Wealth Management LLC’s portfolio, making the stock its 14th largest position. Motley Fool Wealth Management LLC’s holdings in BioMarin Pharmaceutical were worth $26,163,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in BMRN. Nuveen LLC bought a new stake in shares of BioMarin Pharmaceutical during the first quarter worth $184,475,000. AQR Capital Management LLC grew its holdings in shares of BioMarin Pharmaceutical by 127.9% during the first quarter. AQR Capital Management LLC now owns 2,925,805 shares of the biotechnology company’s stock worth $203,987,000 after purchasing an additional 1,642,206 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of BioMarin Pharmaceutical by 212.7% during the first quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock worth $112,607,000 after purchasing an additional 1,083,512 shares during the last quarter. Fuller & Thaler Asset Management Inc. bought a new stake in shares of BioMarin Pharmaceutical during the first quarter worth $59,125,000. Finally, Robeco Institutional Asset Management B.V. grew its holdings in shares of BioMarin Pharmaceutical by 559.8% during the second quarter. Robeco Institutional Asset Management B.V. now owns 641,718 shares of the biotechnology company’s stock worth $35,275,000 after purchasing an additional 544,457 shares during the last quarter. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Trading Down 3.3%

NASDAQ:BMRN opened at $52.67 on Tuesday. BioMarin Pharmaceutical Inc. has a 1-year low of $51.56 and a 1-year high of $73.51. The business’s 50-day moving average price is $55.20 and its two-hundred day moving average price is $57.22. The company has a current ratio of 5.56, a quick ratio of 3.60 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $10.11 billion, a price-to-earnings ratio of 15.63, a PEG ratio of 0.68 and a beta of 0.33.

Analysts Set New Price Targets

Several brokerages have recently commented on BMRN. Weiss Ratings restated a “sell (d+)” rating on shares of BioMarin Pharmaceutical in a report on Wednesday, October 8th. Zacks Research cut BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. JPMorgan Chase & Co. increased their target price on BioMarin Pharmaceutical from $116.00 to $119.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Raymond James Financial began coverage on BioMarin Pharmaceutical in a research note on Wednesday, September 3rd. They set an “outperform” rating and a $85.00 price target on the stock. Finally, Wolfe Research set a $95.00 price objective on BioMarin Pharmaceutical and gave the stock an “outperform” rating in a report on Tuesday, July 15th. Thirteen analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, BioMarin Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus target price of $93.26.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.